Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Geron Corporation GERN

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:GERN)

Fundamentals Snapshot (NDAQ:GERN)

Opinion & Analysis (NDAQ:GERN)

Drug pricing, presidential politics, and three biotechs with promise

The Life Sciences Report April 13, 2016

Stock picks including a coal play

J.W. Cotton November 4, 2009

Profiting from the 'picks and shovels' of stem cell research

Andrew Mickey January 27, 2009

Make money from the next emerging boom

Andrew Mickey November 25, 2008

Cash-rich companies for the bear-market bounce

Jason Schwarz November 7, 2008

Bullboard Posts (NDAQ:GERN)

GERON CORPORATION: A LOT IS RIDING ON IMETELSTAT!

$GERN Geron Corporation (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor,...
AviseAnalytics - June 17, 2022

still holding this stock

my target of $3 per share should be easily reached in the quarter,so glta shareholders.
coolfooldumbguy - February 13, 2019

this was way oversold

people always seem to over react with panic,so glta.
coolfooldumbguy - October 5, 2018

the bottom is past

for it,so glta who bought a few days ago,but it looks like a good performer.
coolfooldumbguy - October 5, 2018

the bottom is past

it is a buy today for this one,so glta.
coolfooldumbguy - October 3, 2018

waiting for a bottom here

might get to a dollar,so it will be a buy at some point for bargain hunters.
coolfooldumbguy - September 28, 2018